Meet Leslie, a 42-year-old mother of three children aged 2, 5, and 7. Leslie's oncologist has just informed her that she has Stage III Ovarian Cancer.
Leslie has a 25% chance of living to see her youngest's 7th birthday. Women like Leslie represent the challenge and opportunity
for the transformation of ovarian cancer therapies. Many of these women develop multi-drug resistant tumors. This is when
cancer cells develop attributes that resist multiple drugs due to a number of mutations in the cell that limit the
effectiveness of current treatment regimens. Finding solutions to this challenge represents a chance to extend the life of
women like Leslie.
Nemucore Medical Innovations Inc is a clinical development company dedicated to the development and commercializations of
life-saving nanomedicines for the treatment of multi-drug resistant cancers. Nemucore has a suite of three core
technologies, designated NMI-Rx, that allow for formulation of nanomedicines which have improved drug delivery
attributes to address multi-drug resistant cancer. These attributes enable products to achieve superior resident times,
targeted delivery, and controlled release properties.
Nemucore is actively partnering with biopharmaceutical firms who are developing drugs that can benefit from NMI-Rx's
superior delivery attributes to bring new products to market and provide patients with life-threatening cancers,
like Leslie, a new hope.